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The role of secreted frizzled-related protein (SFRP) genes in gastric cancer remains largely unknown. We determined the frequency
and functional significance of SFRPs hypermethylation in human gastric cancer. The expression and methylation status of four SFRP
members (SFRP1, 2, 4, and 5) in primary gastric cancer samples was screened. The biological effects of SFRP were analysed by flow
cytometry, cell viability assay and in vivo tumour growth in nude mice. Among the four SFRPs, only SFRP2 was significantly
downregulated in gastric cancer as compared to adjacent non-cancer samples (Po0.01). Promoter hypermethylation of SFRP2 was
detected in 73.3% primary gastric cancer tissues, 37.5% of samples showing intestinal metaplasia and 20% adjacent normal gastric
tissues. Bisulphite DNA sequencing confirmed the densely methylated SFRP2 promoter region. Demethylation treatment restored
the expression of SFRP2 in gastric cancer cell lines. Forced expression of SFRP2 induced cell apoptosis, inhibited proliferation of gastric
cancer cells and suppressed tumour growth in vivo. Moreover, methylated SFRP2 was detected in 66.7% of serum samples from
cancer patients but not in normal controls. In conclusion, epigenetic inactivation of SFRP2 is a common and early event contributing to
gastric carcinogenesis and may be a potential biomarker for gastric cancer.
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Epigenetic silencing of tumour-related genes due to CpG island
hypermethylation has emerged as one of the most important
alternations in gastric cancer development (Leung et al, 2001; Yu
et al, 2003). We have previously shown that tumour-related genes
including E-cadherin, p15, and p16 were frequently methylated in
gastric cancer (Leung et al, 2001) as well as in pre-malignant
gastric lesions (Leung et al, 2006), suggesting dysregulation in
CpG-island methylation is likely to be involved in the early gastric
carcinogenesis process.
Wnt proteins are secreted signalling factors with multiple
functions in development and tumourigenesis (Polakis 2007).
Wnt binding to frizzled receptors leads to the cytosolic stabilisa-
tion and accumulation of b-catenin, which translocates to the
nucleus and forms a complex with T-cell factor transcription
factors, thereby regulating target gene expression. Frizzled and
secreted frizzled-related proteins (SFRPs), a family of five secreted
glycoproteins, are identified as possible negative modulators of the
Wnt signal transduction pathway (Heller et al, 2002). The SFRPs
are activated through the binding of Wnt proteins to the
membrane-bound frizzled receptors, leading to the stabilisation
and increase in levels of the transcription factor b-catenin (Ilyas
2005). Activation of SFRPs results in constitutive activation of Wnt
signalling and is associated with inhibition of apoptosis (Melkonyan
et al, 1997; Ko et al, 2002), suggesting a critical role of the SFRP
genes in the control of Wnt signal pathway. Disruption of this
pathway by downregulation of the SFRP genes through promoter
methylation has been shown in a few human cancers including
colon (Suzuki et al, 2004), bladder (Marsit et al, 2005), oesophagus
(Zou et al, 2005), lung (Fukui et al, 2005), and head and neck
cancers (Marsit et al, 2006). However, the role Wnt-antagonist
genes including SFRP1, SFRP2, SFRP4, and SFRP5 in gastric cancer
remains poorly defined. We have previously shown that SFRP was
expressed in most of the adjacent non-cancer gastric samples but
downregulated in 16% of gastric cancer samples (To et al, 2001).
Moreover, Kirikoshi et al (2001) showed that FZD2, 5, 7, 8, 9, and
10 were upregulated in gastric cancer cell lines.
In the present study, we first determined the expression level of
SFRPs in gastric cancer and adjacent non-cancer tissues from
gastric cancer patients. Secondly, we examined the methylation
status of SFRP genes in gastric cancer and explored the functional
significance of methylation-induced silencing of SFRP gene
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further evaluated the potential use of detecting methylated SFRP
DNA in serum as a biomarker for gastric cancer diagnosis.
MATERIALS AND METHODS
Human gastric samples
A total of 35 primary gastric adenocarcinomas and their adjacent
non-cancer specimens, 24 benign gastric mucosa with intestinal
metaplasia, and 10 normal gastric specimens from patients with
normal endoscopy were obtained from the Endoscopy Centre of
the Prince of Wales Hospital. All specimens were immediately
snapped frozen in liquid nitrogen and stored at  801C until
processing. Serum samples were obtained from 18 gastric cancer
patients and 18 normal controls without gastric cancer. All
subjects gave informed consent for obtaining the study materials.
The study protocol was approved by the Clinical Research Ethics
Committee of the Chinese University of Hong Kong.
Cell lines and cell culture
A total of seven gastric cancer cell lines (Kato III, MKN-28, MKN-
45, SNU-1, SNU-16, AGS, and NCI-N87) were obtained from Riken
Gene Bank (Japan) and American Type Culture Collection
(Manassas, VA, USA). Cells were cultured in RPMI 1640
(Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine
serum at 5% CO2,3 7 1C, and 95% humidity.
Reverse transcription, polymerase chain reaction
(RT–PCR) and real-time RT–PCR
Since SFRP3 does not contain a CpG island of more than 200bp,
we only examined the gene expression levels of SFRP1, SFRP2,
SFRP4, and SFRP5 in this study. Total RNA was extracted from 14
pairs of gastric cancer specimens and 7 gastric cancer cell lines by
Trizol reagent (Gibco BRL, Life Technologies, Invitrogen) accord-
ing to the manufacturer’s instruction. Reverse transcription
reaction was performed using 2mg of total RNA with a first strand
cDNA kit (Promega, Madison, WI, USA). The mRNA expression
levels of the SFRPs were determined by PCR (PTC-200, MJ
Research, Waltham, MA, USA) and quantitative real-time PCR
(LightCycler, Roche Diagnostic, Germany). Probe Design software
(Roche Diagnostic) was used for designing PCR primers
(Table 1A). Glyceraldehyde-3-phosohate dehydrogenase (GAPDH)
was used as an internal control of RNA integrity. The ratio of
SFRPs to GAPDH expression was determined by Relative
Quantification Software (Roche Diagnostic).
Bisulphite treatment of DNA, methylation-specific
polymerase chain reaction (MSP) and quantitative
methylation-specific PCR
Genomic DNA was extracted from 30 pairs of gastric cancer
tissues, 24 benign gastric mucosa with intestinal metaplasia, and 10
normal gastric specimens or cell lines by a DNA mini kit (Qiagen,
Valencia, CA, USA). Methylation statuses of SFRP1, SFRP2, SFRP4,
and SFRP5 in gastric tissues and cell lines were determined by
MSP. Briefly, 2mg of genomic DNA was bisulphite-treated with
Zymo DNA Modification Kit (Zymo Research, Orange, CA, USA).
Bisulphite-treated DNA was used as a template for MSP and
quantitative PCR by ABI 2700 thermocycler (Applied Biosystems,
CA, USA) and LightCycler (Roche Diagnostic), respectively.
OLIGO 6 software (Molecular Biology Insights, CO, USA) was
used for designing primers specific for methylated and unmethy-
lated alleles (Table 1B). CpGenomet universal methylated DNA
(Chemicon International Inc., CA, USA) was used as positive
control for methylation and water was used as a negative control
for each amplification. To quantify the amount of DNA methyla-
tion, the methylated DNA was determined by the threshold cycle
number for each sample against a standard curve generated by
Table 1 List of primer sequences
(A) Primer sequences for RT–PCR
SFRP1
Sense 50-CCAGCGAGTACGACTACGTGAGCTT-30
Anti-sense 50-CTCAGATTTCAACTCGTTGTCACAGG-30
SFRP2
Sense 50-GATGATGACAACGACATAATGGAAACG-30
Anti-sense 50-GAGTGTGCTTGGGGAACGGGAGCT-30
SFRP4
Sense 50-GGTACAGGAAAGGCCTCTTGATGTTG-30
Anti-sense 50-GGATCTTTTACTAAGCTGATCTCTCC-30
SFRP5
Sense 50-TGCGCCCAGTGTGAGATGGAGCAC-30
Anti-sense 50-CCCATCCCTTAGGCCTTGTGCCAGT-30
GAPDH
Sense 50-GGAGTCAACGGATTTGGT-30
Anti-sense 50-GTGATGGGATTTCCATTGAT-30
(B) Primer sequences for MSP
SFRP1
Methylated sense 50-TGTAGTTTTCGGAGTTAGTGTCGCGC-30
Methylated
anti-sense
50-CCTACGATCGAAAACGACGCGAACG-30
Unmethylated
sense
50-GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT-30
Unmethylated
anti-sense
50-CTCAACCTACAATCAAAAACAACACAAACA-30
SFRP2
Methylated sense 50-GGGTCGGAGTTTTTCGGAGTTGCGC-30
Methylated
anti-sense
50-CCGCTCTCTTCGCTAAATACGACTCG-30
Unmethylated sense 50-TTTTGGGTTGGAGTTTTTTGGAGTTGTGT-30
Unmethylated
anti-sense
50-AACCCACTCTCTTCACTAAATACAACTCA-30
SFRP4
Methylated sense 50-GGGTGATGTTATCGTTTTTGTATCGAC-30
Methylated
anti-sense
50-CCTCCCCTAACGTAAACTCGAAACG-30
Unmethylated
sense
50-GGGGGTGATGTTATTGTTTTTGTATTGAT-30
Unmethylated
anti-sense
50-CACCTCCCCTAACATAAACTCAAAACA-30
SFRP5
Methylated sense 50-AAGATTTGGCGTTGGGCGGGACGTTC-30
Methylated
anti-sense
50-ACTCCAACCCGAACCTCGCCGTACG-30
Unmethylated
sense
50-GTAAGATTTGGTGTTGGGTGGGATGTTT-30
Unmethylated
anti-sense
50-AAAACTCCAACCCAAACCTCACCATACA-30
b-actin
Sense 50-TGGTGATGGAGGAGGTTTAGTAAGT-30
Anti-sense 50-AACCAATAAAACCTACTCCTCCCTTAA-30
(C) Primer sequences for bisulphite DNA sequencing
SFRP1
Sense 50-TGGTTTTGTTTTTTAAGGGGTGTTGAGT-30
Anti-sense 50-TCCTACCRCAAACTTCCAAAAACCTCC-30
SFRP2
Sense 50-AATTAGATTTAGAAAGTAGTGATTAGT-30
Anti-sense 50-AACCAAAACCCTACAACATCGTAAAC-30
SFRP4
Sense 50-GAGGGGGTGATGTTATYGTTTTTGTAT-30
Anti-sense 50-CCCCAAACTCCAATCRACAACAAAAC-30
SFRP5
Sense 50-GGGAGGTAGGGAGTTTTGGGGAGAA-30
Anti-sense 50-CCCAAATAAATAACAACCTACRCTAC-30
Abbreviations: RT–PCR¼reverse transcription–PCR; SFRP¼secreted frizzled-
related protein; GAPDH¼glyceraldehyde-3-phosohate dehydrogenase; MSP¼
methylation-specific polymerase chain reaction.
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USA). The results were expressed as the ratio of methylated DNA
to that of b-actin. Samples with a ratio of 40.5 were considered to
have a high level of DNA methylation (Chan et al, 2005).
Bisulphite sequencing
For bisulphite DNA genomic sequencing, 2ml of bisulphite-treated
DNA was amplified using primers list in Table 1C. The PCR
products were electrophoresed and cloned into the pCR2.1–TOPO
cloning vector (Invitrogen). A total of 8–10 colonies were
randomly chosen for plasmid DNA extraction with Qiaprep Spin
Mini kit (Qiagen). Plasmid DNA was sequenced using the ABI
PRISM BigDye Terminator Cycle Sequencing Kit in ABI 3100
sequencer (Applied Biosystems). Sequencing analysis was per-
formed by SeqScape software (Applied Biosystems).
Construction of expression plasmids
The full-length pcDNA3.1(þ)SFRP2 clone was made by cloning of
the full-length PCR product of SFRP2 with PFU DNA polymerase
(Invitrogen). All the plasmid sequences and orientations were
confirmed by DNA sequencing.
Western blot
A total of 20mg of protein of each sample was loaded in 12.5%
sodium dodecyl sulfate/polyacrylamide gel electrophoresis. The
proteins on the polyacrylamide gel were transferred to a member
for antibody incubation. Polyclonal SFRP2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and the corresponding
secondary antibody (Santa Cruz Biotechnology) were applied
before immunoblotting. Immunoblots were developed by using
the enhanced chemiluminescence detection system (Amersham,
Piscataway, NJ, USA) according to the manufacturer’s protocol.
Human b-actin was used as the control of protein integrity.
Cell proliferation assay
Transiently transfected MKN45 cells with or without SFRP2
expression vector were selected for proliferation assay. Cells were
seeded in 96-well plates. The colorimetric MTs (Promega) assay
was used to measure cell numbers at 24 and 48h. Experiment was
performed in triplicates.
Flow cytometric (FCM) detection
Cell cycle analysis was carried out by FCM. Briefly, cells transfected
with or without SFRP2 were removed and washed twice with PBS at
24 and 48h. The cells were then fixed in ice-cold ethanol for 1h.
The samples were concentrated by removing the ethanol and
treated with 0.01% RNase (10mgml
 1, Sigma, St Louis, Mo, USA)
for 10min at 371C. Cellular DNA was stained with 0.05%
propidium iodide for 20min at 41C in dark. The cell cycle
distribution was determined using a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA, USA) and 10000 cells
were analysed with MultiCycle software package (Phoenix, San
Diego, CA, USA).
Nude mice assay
Transiently transfected SFRP2/MKN45 cells, mock-transfected cells
and parental MKN45 cells were re-suspended in fresh PBS and
counted. MKN45 (1 10
6 cells) with or without SFRP2 expression
vector was injected subcutaneously into the dorsal flank of nude
mice (five per group). The time interval of tumour occurrence and
the dimension of the tumour were recorded every 3 days until the
end of week 3. The animal study protocol was approved by the
Animal Experimentation Ethics Committee of the Chinese
University of Hong Kong and all procedures were performed in
compliance to the guidelines of the United Kingdom Co-ordinating
Committee on Cancer Research.
Two perpendicular tumour diameters, width and length, were
obtained with calipers and used to calculate tumour volume with
the following formula: tumour volume¼length width
2 0.52
(Yagi and Bekesi, 1990). The experiment was repeated three times.
Statistical analysis
The results were expressed as mean±s.d. or percentage where
appropriate. Mann–Whitney U-test was used to compare the two
sample groups including in vivo tumour growth, percentage of
methylation, age, sex, and the difference in mRNA levels between
cancer and non-cancer specimens. Student’s t-test was used to
compare the differences of SFRP2 expression on the effect of cell
apoptosis and cell proliferation. w
2 test was used for comparison of
methylation frequency and Helicobacter pylori infection. All
statistical calculations were done using SPSS version 11.0 for
windows (SPSS Inc., Chicago, IL, USA). A P-value of o0.05 was
taken as statistical significance.
RESULTS
Gene silencing and methylation status of SFRPs in primary
human gastric cancers
We determined the mRNA expression of SFRPs in 14 pairs of
primary human gastric cancers and adjacent non-cancerous
tissues by quantitative RT–PCR. When compared to adjacent
non-cancer tissues, SFRP2 was found to be significantly down-
regulated in primary gastric tumour specimens (Figure 1).
However, this difference was not seen in SFRP1, SFRP4, and
SFRP5.
To investigate the role of promoter methylation in silencing of
SFRPs in human gastric cancers, the methylation status of SFRPs
was studied in 30-paired gastric cancer specimens and their non-
cancer tissue by MSP (Table 2). For SFRP2, 22 (73.3%) gastric
cancer specimens had SFRP2 methylation, which was significantly
higher than that of adjacent non-cancer tissue (20%, Po0.0001)
(Table 2). There was also no significant difference in the
methylation status between cancer and adjacent non-cancer areas
in other SFRPs. Notably, SFRPs methylation was not seen in gastric
specimens from 10 controls without gastric cancer. In addition,
quantitative MSP was performed to quantify the degree of
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Figure 1 mRNA expression levels of secreted frizzled-related proteins
(SFRPs) in primary gastric cancer (Tumour) and their adjacent non-cancer
tissues (Normal) as determined by quantitative real-time PCR. The results
were expressed as the ratio of copies of target gene relevant to GAPDH
form three independent experiments (n¼14). Data are expressed as
mean±s.d., *Po0.01.
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smethylation in primary gastric cancer. Consistent with the semi-
quantitative MSP results, the mean methylation level of SFRP2 was
significantly higher in cancer than in adjacent non-cancer speci-
men (Po0.001). We also determined the correlation between
H. pylori infection and SFRP2 methylation. H. pylori infection was
detected in 59% of gastric cancer tissues with methylation in
SFRP2 gene and 43% of gastric cancer tissues without SFRP2
methylation (P¼0.69). There was no association between promo-
ter hypermethylation of SFRP2 gene and the status of H. pylori
infection. In addition, there was no significant association between
SFRP2 methylation and the clinico-pathological characteristics of
cancer including age, sex, tumour type, tumour differentiation,
and prognosis for patients (Table 3).
SFRP2 expression could be restored with 50Aza-dC
treatment in gastric cancer cell lines
As shown in Figure 2A, SFRP2 was silenced in all seven human
gastric cancer cell lines. We examined the role of methylation in
the silencing of SFRP2. Using MSP, SFRP2 methylation was
detected in all these seven cell lines with silenced expression
(Figure 2B). To confirm that CpG methylation is indeed
responsible for the silencing of SFRP2, we treated these heavily
methylated and silenced cell lines with 5-Aza-DC, a methyltrans-
ferase inhibitor. SFRP2 expression was markedly induced after the
treatment in all the cell lines (Figure 2A). These results
demonstrate that CpG methylation directly contributes to the
silencing of SFRP2 in tumour cells.
Bisulphite sequencing of SFRP2
To verify the MSP findings and to study the extent of promoter
methylation of SFRP2, we performed high-resolution bisulphite
genomic sequencing in the seven cell lines, four gastric cancers
with low or silenced SFRP2 expression, and in their adjacent non-
cancer tissues. The area of the CpG-rich region around the
transcription initiation site of SFRP2 gene between the nucleotides
 362 and þ9 which spanned 34 CpG site was sequenced
(Figure 3). There was extensive methylation in the promoter
region of the MKN28 cell lines and gastric cancer tissue with low or
silenced SFRP2 expression, whereas a very few methylated CpG
sites were detected in adjacent non-cancer gastric tissues.
Demethylation treatment slightly reduced the methylation density
in MKN28 cells.
SFRP2 inhibits tumour cell proliferation and induces cell
apoptosis in vitro
The frequent silencing of SFRP2 by methylation in gastric cancer
but not in adjacent gastric mucosa suggests a potential tumour
suppressor role of this gene. To test this speculation, we examined
the effect of SFRP2 transfection on cell proliferation and apoptosis
of gastric cancer cells. SFRP2 expression vector was transiently
transfected into MKN45 cell line with complete methylation and
silencing of SFRP2. Forced expression of SFRP2 in transfected
MKN45/SFRP2 cells was confirmed by RT–PCR (Figure 4A) and
western blot (Figure 4B). After 48h of transfection, cell viability
was reduced from 0.77 to 0.56 (Po0.001) (Figure 4C) as
determined by cell proliferation assay. Cell apoptosis as deter-
mined by sub-G1 phase cells was significantly induced from 0.12 to
3.79% at 24h (Po0.05) and from 0.56 to 8.1% at 48h (Po0.001)
(Figure 5).
SFRP2 inhibits gastric tumour growth in vivo
In light of the observed anti-proliferative and pro-apoptotic effects
of SFRP2 on MKN45 in vitro, we tested whether SFRP2 would alter
Table 3 Patients’ characteristics and methylation status
SFRP1 SFRP2 SFRP4 SFRP5
Patient Sex Age
Lauren
type H. pylori NTNTNTNT
1 F 78 Mix Pos + + – + – – + –
2 M7 0 — — ++–++++–
3 M 54 Int Pos + + – + – – + +
4 F 77 Diff Pos + + – + – –   –
5 F8 3 — — ++–+–++–
6 M 73 Diff Neg + + + + – – + –
7 M 66 Diff Neg + – + + – – + –
8 F 81 Diff Neg + – – – – – + +
9 M 42 Diff Neg – + – + – –   +
1 0 M4 8 — — ++–+––++
11 M 79 Int Neg + + + – + – + +
1 2 F7 2 — — ++++++–+
13 F 86 Int Pos + + + – + – + +
1 4 M6 9 I n t N e g ++–+–+–+
15 F 69 Mix Pos – + – + – – – –
16 M 58 — Pos + – – + – – – –
17 M 50 Diff neg + + – – – – + +
18 M 42 Int Pos + + – – – – + +
19 F 80 Int Pos + + – – – – – +
2 0 M7 7 — — –+–+––––
21 M 39 Int Neg + + – + – + + +
22 F 32 Diff Neg – + – – – – – +
23 M 62 Int Pos + + – + – + – +
24 M 49 Int Pos + + – + – + – +
25 M 57 Int Neg + + – – + – + +
26 M 77 Int Pos + + + + + – – +
2 7 M7 0 I n t N e g –+–+–+–+
28 F 61 Diff Pos + + – + – – + +
29 M 76 Int Pos + + – + – + – +
30 F 73 Mix Neg + + – + – – – +
Abbreviations: SFRPs¼the role of secreted frizzled-related proteins; T¼tumour;
N¼adjacent non-tumour; Int¼intestinal; Diff¼diffuse; Pos¼positive; Neg¼nega-
tive; +¼methylation.
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Figure 2 (A) The mRNA expression of secreted frizzled-related protein
2( SFRP2) in gastric cancer cell lines (MKN28, MKN45, AGS, Kato III, NCI87,
SNU1, and SNU16) treated with or without demethylation agent 50Aza-
DC as determined by RT–PCR. Pharmacologic treatment with 50Aza-DC
(50Aza) restored the expression of SFRPs in tumour cell lines. (B) The
methylation status of SFRP2 in gastric cancer cell lines treated with or
without 50-Aza-DC as determined by methylation specific PCR. M:
methylated primers; U: unmethylated primers.
Table 2 Frequency of SFRPs methylation in primary gastric samples
Adjacent non-tumour tissues Tumour
No. Methylated % No. Methylated % P-value
SFRP1 30 25 83.3 30 27 90 40.05
SFRP2 30 6 20 30 22 73.3 o0.0001
SFRP4 30 6 20 30 9 30 40.05
SFRP5 30 15 50 30 9 30 40.05
Abbreviation: SFRPs¼secreted frizzled-related proteins.
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sthe growth of gastric cancer cells in vivo (Figure 6A). The tumour
growth curve of transiently transfected MKN45/3.1-vector control
and MKN45/SFRP2 expression vector in nude mice was shown in
Figure 6B. The mean tumour volume was significantly smaller
in SFRP2-transfected nude mice as compared to the nude mice
with MKN45/3.1-vector control (Po0.0001).
Methylation of SFRP2 in pre-neoplastic gastric lesion
To determine the onset time of SFRP2 methylation in the gastric
carcinogenesis process, we examined endoscopic gastric specimens
containing foci of intestinal metaplasia, a pre-neoplastic lesion,
from patients without gastric cancer. Among the 24 samples with
intestinal metaplasia, 9 (37.5%) had promoter methylation in
SFRP2 detected.
Methylation of SFRP2 in serum samples of gastric cancer
patients
To further investigate whether SFRP2 methylation could be used as
a biomarker for gastric cancer, serum samples of gastric cancer
patients were tested for methylated SFRP2 DNA. A total of 12 of 18
(66.7%) serum samples from cancer patients had SFRP2 methyla-
tion detected whereas SFRP2 methylation was not detected in the
serum of 18 normal subjects.
DISCUSSION
The inappropriate activation of Wnt signalling through mutation
of b-catenin or APC and/or downregulation of negative regulators
such as SFRPs occurs frequently in cancers. The function of SFRPs
as antagonist of the Wnt pathway provides a potential mechanism
to suppress the abnormal activation of this pathway. Wnt signal
activation by mutant b-catenin or APC could be suppressed
partially by overexpression of SFRPs (Suzuki et al, 2002, 2004).
Our previous study has shown that SFRP was downregulated in
gastric cancer (To et al, 2001) and may carry a tumour suppressor
potential. To address whether epigenetic mechanisms were
responsible for SFRP downregulation, we extend the study to
determine the mRNA expression level and the methylation status
of SFRPs in gastric cancer. Among the four SFRPs with CpG islands
in the promoter region, we found that only SFRP2 was silenced and
methylated in gastric cancer. Promoter methylation of SFRP2 was
specifically associated with low or absent mRNA expression in
gastric cancer. The CpG island methylation status of SFRP2 was
further confirmed by bisulphite sequencing. In addition, we
confirmed that the SFRP2 expression was restored after the
demethylating agent, 5-aza-20-deoxycytidine, treatment in gastric
cancer cell lines. These data suggested that hypermethylation of
the promoter region might be critical for the transcriptional
silencing of SFRP2 in gastric cancers.
The functional role of SFRP2 in gastric cancer cells remains
unclear and was further evaluated by examining the inhibitory
effect of SFRP2 expression on tumour cells. Forced expression of
SFRP2 in gastric cancer cell line MKN45 with hypermethylated
SFRP2 inhibits cell proliferation, induces cell apoptosis,
and inhibits in vivo tumour growth. Consistent with these
findings, Suzuki et al (2004) demonstrated that overexpressed
SFRPs reduced colony formation and induced apoptosis in
colon cancer cells. Taken together, these data highly suggest
that SFRP2 acts as a functional tumour suppressor gene in gastric
cancer and its silencing may enhance tumour growth and
expansion.
Chr4 (q31.3)
SFRP2 Exon 1
CpG islands
<20%
>80%
20–39%
40–59%
60–79%
First-exon and promoter prediction
Promoter
601N
Adjacent
non-cancer
gastric
samples
Primary
gastric
cancer
190N
45N
Cell
lines
187N
601T
190T
45T
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MKN28 5′ Aza
MKN28 con
Exon 1 (–362 to +9)
MSP position (–81 to –219)
Figure 3 A representative picture of bisulphite sequencing in secreted frizzled-related protein 2 (SFRP2) gene. The CpG island, MSP region ( 219 to
 81) and bisulphite sequence region ( 362 to þ9) were shown in the upper panel. A 371-bp region with 34 CpG site was analysed. Each row of CpG
sites represented an individual allele of the SFRP2 promoter analysed. Percentage methylation was determined as percentage of methylated cytosine from 8
to 10 randomly sequenced colonies.
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sRecent epigenetic studies have suggested that silencing of the
genes by DNA hypermethylation at CpG islands tended to be
accumulated in the multi-step pathway of gastric carcinogenesis
(Kang et al, 2001; To et al, 2002; Waki et al, 2002). Promoter
methylation of tumour suppressor genes has been detected in early
stages of gastric cancer development (Tamura 2002; Waki et al,
2002). In this study, methylation of SFRP2 was detected in
intestinal metaplasia, a pre-neoplastic gastric lesion, which
implicates their early involvement in the multi-step gastric
carcinogenesis process. Our results showed that the frequency of
hypermethylation decreased from 73.3% in gastric cancer to 37.5%
in intestinal metaplasia and 20% in adjacent non-cancer tissues. It
thus appears that epigenetic alteration of SFRP2 is present in the
pre-neoplastic stage even in patients without gastric cancer, which
may be an important mechanism leading to malignant transfor-
mation. Since not all intestinal metaplasia (IM) will progress to
gastric cancer and promoter hypermethylation is not detected in
all gastric cancers, follow-up study is required to elucidate the
prognostic value of detecting promoter hypermethylation in IM.
Thus, detection of hypermethylation may have the potential
of identifying individuals at risk for further histological
progression.
The detection of SFRP2 methylated DNA in serum samples of
gastric cancer patients further implies their potential diagnostic
value in gastric cancer. Whilst we have previously shown that
methylated DNA could also be detected in cancer patients’ blood
(Lee et al, 2002; Leung et al, 2005), it is therefore valuable to
explore the possible application of SFRP2 as a serum molecular
biomarker for detection of human gastric cancer. We found that
SFRP2 was detected in 67% of serum samples of cancer patients.
This is higher than the previous reports in which 44–55% of
gastric cancer patients had methylation detected with the use of
multiple markers (Koike et al, 2004; Leung et al, 2005). Our finding
suggests that SFRP2 is a potential source of circulating methylated
DNA. Studies with larger sample size are necessary to discern the
early diagnostic and prognostic significance of detecting SFRP2
methylation in the serum of gastric cancer patients with different
subtypes.
In conclusion, we found that SFRP2 is hypermethylated in
gastric cancer. Although widely expressed in non-cancer samples,
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Figure 5 Effect of SFRP2 on apoptosis of human gastric cancer cells.
SFRP2 increased the rate of apoptosis in MKN45 cells transfected with
pcDNA3.1(þ)SFRP2, as determined by the number of cells with sub-G1
DNA content by flow cytometry. Values are expressed as the mean±s.d.
of three replicate experiments. *Po0.001.
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Figure 4 Transient transfection of secreted frizzled-related protein 2
(SFRP2) gene in MKN45 cell lines. (A) Strong SFRP2 mRNA expression was
observed in MKN45 cells transfected with pcDNA3.1(þ)SFRP2, but not in
cells transfected with the empty vector. (B) Strong SFRP2 protein
expression was observed in MKN45 cells transfected with
pcDNA3.1(þ)SFRP2, but not in cells with empty vector of in parental
MKN45. (C) SFRP2 significantly suppressed cell viability at 48h. Values are
expressed as the mean±s.d. from three independent experiments
(*Po0.001).
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Figure 6 Secreted frizzled-related protein 2 (SFRP2) inhibits growth of
tumours derived from MKN45 in vivo.( A) A representative picture of nude
mice: at week 3 nude mice injected with MKN45/3.1 and MKN45/SFRP2.
(B) The tumour volume of vector (pcDNA3.1) transfected MKN45 cell in
nude mice (n¼15) was indicated as mean tumour volume±s.d. (mm
3).
Tumour mean volume of MKN45/SFRP2 mice was significantly smaller than
the MKN45/3.1 nude mice group (*Po0.001).
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further demonstrated that SFRP2 could act as a functional tumour
suppressor gene in gastric cancer. The high detection rate of
methylated SFRP2 in serum indicates that SFRP2 methylation has
its diagnostic and therapeutic values in gastric cancer.
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